Navigation Links
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
Date:6/22/2009

SEATTLE, June 22 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has exercised its option under the terms of its collaboration agreement with Trubion to extend the research period for an additional one-year period through Dec. 22, 2010. Under the terms of the research period extension, Wyeth's obligations to Trubion include collaboration research funding commitments of approximately $3.3 million in exchange for committed research services through Dec. 22, 2010.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

"We are pleased that Wyeth has extended the research period of our collaboration," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "Wyeth's ongoing commitment to the collaboration underscores the potential of our technology, and we look forward to continuing our efforts with Wyeth as we pursue the development of additional first-in-class and best-in-class compounds."

In December 2005, Trubion entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of TRU-015 and other CD20-directed therapeutics. The agreement also includes the development and worldwide commercialization of certain other product candidates directed to a small number of targets other than CD20 that have been established pursuant to the agreement. Unless earlier terminated, the agreement will remain in effect on a product-by-product basis and on a country-by-country basis until the later of the date that any such product shall no longer be covered by a valid claim of a U.S. or foreign p
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
2. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
3. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
4. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
5. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
6. Trubion Announces Presentations at Upcoming Investor Conferences
7. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
8. Trubion Announces Presentations at Upcoming Investor Conferences
9. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
10. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Bed bugs compromised Penn State. A report ... Meanwhile, My Cleaning Products offered complimentary samples of its bed ... without using harmful chemical elements. , Based on the ... building was actually a dormitory , My Cleaning Products ... May 13 and bed bug presence was confirmed on May ...
(Date:5/23/2013)... DE (PRWEB) May 23, 2013 Just released ... by executive coach and author Barbara Roche: “Commit to Confidence: ... Out.” , Filled with helpful tips and quotes from the ... business leaders, and tangible exercises that readers can do on ... how to achieve their personal and professional goals. ...
(Date:5/22/2013)... 22, 2013 iLuv Creative Technology, the ... for the mobile lifestyle, announces they are now shipping ... manage multiple iPad devices efficiently. Winner of the 2013 ... Good Design award, MultiCharger-X is revolutionizing the way businesses, ... is deployed. , MultiCharger-X (iAD910) combines ...
(Date:5/22/2013)... May 22, 2013   Oligomerix, Inc. , ... disease modifying therapeutics for Alzheimer,s disease (AD) and ... its Series B financing, which includes both issuance ... would represent approximately $2.8M in new investments in ... supported the raise. Funding from ...
Breaking Biology Technology:Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3
... Uroplasty, Inc. (Amex:,UPI) announced today that it will ... on Monday, November 10, 2008 at the New York,Palace ... Chief Executive,Officer and Medi Jiwani, Vice President and Chief ... financial,performance at 4:55 p.m. Eastern Time., Attendance at ...
... DIEGO, Nov. 4 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... of ADVENTRX, is scheduled to present at the Rodman ... scheduled to present,on Tuesday, November 11th, 2008 at 2:50 ... place November 10-12, 2008 at the,Palace Hotel in New ...
... technology is one of the rapidly growing markets in life science ... is projected to reach $2.2 billion. Major factors that continue to ... the existing and emerging technologies. , ... San Jose, ...
Cached Biology Technology:Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York 2World Gene Amplification Technologies Market to Reach $2.2 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 2World Gene Amplification Technologies Market to Reach $2.2 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 3
(Date:5/23/2013)... unnecessarily undergo surgery or harsh treatments because science ... aggressive forms of the disease. Researchers at Case ... are developing technology that allows patients to safely ... treatments or take drastic measures. , The project ... professor of biomedical engineering at Case Western Reserve ...
(Date:5/23/2013)... have succeeded in treating cerebral palsy with autologous cord ... a 2.5 year old boy had been in a ... Just two months after treatment with the cord blood ... following months, the child learned to speak simple sentences ... a Korean study, dispel the long-held doubts about the ...
(Date:5/23/2013)... world,s largest and fastest growing open-access publishers, announces ... in Bioengineering and Biotechnology . , A ... in Bioengineering and Biotechnology will provide a ... and biotechnology research to be disseminated and discussed. ... will provide an open-science and interactive web ...
Breaking Biology News(10 mins):Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... tripled in the last 25 years, putting many children at ... in Academic Pediatrics by an obesity expert at ... Center. "Children are not only becoming obese, but ... Skelton, M.D., lead author and director of the Brenner FIT ...
... Many experimental studies have found that physical exercise ... risks of cardiovascular disease; however, few of these ... ethnic breakdowns. Now, a long-term study of over ... gender- specific data on the cholesterol effects of ...
... from CSIRO,s Food Futures Flagship have made a breakthrough ... noses, (e-noses) by developing a system for comparing their ... fly. "Although e-noses already have many uses such ... air quality they are not as discriminating as ...
Cached Biology News:Research shows rates of severe childhood obesity have tripled 2Health benefits of physical activity more pronounced in women 2E-Noses: Testing their mettle against fly noses 2
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
...
Biology Products: